The effect of antithrombotic therapy on the recurrence and outcome of chronic subdural hematoma after burr-hole craniostomy in a population-based cohort - Summary - MDSpire
Advertisement
The effect of antithrombotic therapy on the recurrence and outcome of chronic subdural hematoma after burr-hole craniostomy in a population-based cohort
To study the effect of antithrombotic therapy (ATT) on the outcome of operatively treated chronic subdural hematomas (CSDH), specifically focusing on recurrence rates and associated risk factors.
Key Findings:
ATT was used by 54.5% of patients at diagnosis.
Hematoma recurrence occurred in 15.8% of patients, with no significant association with ATT (54.2% vs. 55.3%; p = 0.886).
The mean time from primary surgery to reoperation was shorter for patients with ATT, but not statistically significant (43.0 days vs. 54.1 days; p = 0.323).
Interpretation:
The study suggests that ATT does not significantly affect the recurrence of CSDH post-surgery, although patients on ATT may experience a shorter time to reoperation, which could influence clinical decision-making.
Limitations:
Retrospective design may introduce bias.
Limited generalizability due to single-center study.
Potential confounding factors not fully controlled.
Data collection methods may have inherent biases.
Conclusion:
Antithrombotic therapy does not appear to influence the recurrence of chronic subdural hematoma after burr-hole craniostomy in this cohort.
FOXC1 duplications were the second most common monogenic finding among genetically solved juvenile open-angle glaucoma cases in one registry, supporting the use of copy-number variant analysis in early-onset glaucoma testing.
